The risk is even higher for people who take semaglutide drugs like Rybelsus to manage their weight: This group is over 7 times more likely to develop NAION than those who do not take it, according to the studys results
Research findings reveal substantially elevated gastrointestinal risks demonstrating: Pancreatitis Risk : Patients using GLP-1 agonists showed a 9.09-fold increased risk (adjusted hazard ratio) for developing pancreatitis compared to those using alternative weight loss medications Gastroparesis Development : The study revealed a 3.67-fold increased risk for gastroparesis, often occurring secondary to pancreatic inflammation Bowel Obstruction : A 4.22-fold increased risk for intestinal blockages was documented, frequently accompanying severe gastroparesis cases FDA Adverse Event Reports : Analysis of the FDAs FAERS database through 2024 shows over 900 reported cases of pancreatitis specifically linked to semaglutide use Post-Marketing Surveillance : Real-world data from 2023-2024 indicates that serious gastrointestinal events occur more frequently than initially reported in clinical trials When pancreatitis develops, the inflamed pancreas releases numerous enzymes, toxic substances, and vasoactive compounds including inflammatory cytokines that can damage the autonomic nervous system controlling gastric function
Creatine monohydrate (3 to 5 grams daily) is probably the single most evidence-supported supplement for preserving lean mass on a GLP-1-driven caloric deficit, and the creatine and GLP-1 guide makes a compelling case for its inclusion
Learn the mechanism, monitoring schedule, dose-adjustment strategy, and clinical evidence behind this drug interaction
